MMED vs SENS
MMED: MiniMed is a diabetes care technology company specializing in automated insulin delivery pumps, continuous glucose monitors, and smart insulin pens for global Type 1 and Type 2 diabetes management. SENS: Senseonics develops implantable continuous glucose monitoring systems that stay under the skin for up to one year, offering diabetes patients longer intervals between sensor replacements than conventional CGM devices.
Side-by-side fundamentals
| Metric | MMED | SENS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.33 | $4.86 | |
| Market cap as of 2026-07-23 | $4.6B | $260M | |
| Net margin as of 2026-07-23 | -10.7% | -214.2% | MMED higher |
| Gross margin as of 2026-07-23 | +54.2% | +52.1% | MMED higher |
| Operating margin as of 2026-07-23 | -6.1% | -212.9% | MMED higher |
| ROE as of 2026-07-23 | -9.2% | -130.0% | MMED higher |
| ROA as of 2026-07-23 | -7.2% | -67.2% | MMED higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.05 | MMED lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +71.9% | |
| Revenue CAGR (3y) SEC XBRL | +12.1% | +29.1% | SENS higher |
| Beta as of 2026-07-23 | -0.10 | 0.97 | |
| 1-year return as of 2026-07-22 close | -11.7% | -58.1% | MMED higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.